Soligenix

$1.65
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.01 (+0.59%) Today
-$0.05 (-2.94%) As of 8:00 PM EDT after-hours

Why Robinhood?

You can buy or sell Soligenix and other stocks, options, and ETFs commission-free!

About SNGX

Soligenix, Inc. Common Stock, also called Soligenix, is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare disease. Read More It operates through Specialized BioTherapeutics and Public Health Solutions segments. The Specialized BioTherapeutics segment focuses in the development of a novel photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma. The Public Health Solutions solutions comprises active development programs for RiVax, ricin toxin vaccine candidate and SGX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease. The company was founded in 1987 and is headquartered Princeton, NJ. The listed name for SNGX is Soligenix, Inc. Common Stock.

CEO
Christopher J. Schaber
Employees
16
Headquarters
Princeton, New Jersey
Founded
1987
Market Cap
50.74M
Price-Earnings Ratio
Dividend Yield
Average Volume
883.20K
High Today
$2.02
Low Today
$1.62
Open Price
$1.68
Volume
4.01M
52 Week High
$3.54
52 Week Low
$0.8811

Collections

SNGX Earnings

-$0.32
-$0.21
-$0.11
$0.00
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Q2 2020
Q3 2020
Estimated
per share
Actual
Expected Nov 10, Pre-Market

You May Also Like